BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2005) 78, 110-115
© 2005 British Institute of Radiology
doi: 10.1259/bjr/51245688
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Acosta-Gómez, M J
Right arrow Articles by de la Riva-Aguilar, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Acosta-Gómez, M J
Right arrow Articles by de la Riva-Aguilar, A

Full Paper

The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours

M J Acosta-Gómez, MD 1 M A Muros, MD, PhD 1 J M Llamas-Elvira, MD, PhD 1 A Ramírez, MD, PhD 1 S Ortega, MD 1 G Sabatel, MD 1 C Ramos, MD 1 and A de la Riva-Aguilar, MD, PhD 2

1 Department of Nuclear Medicine, Virgen de las Nieves Hospital, Avda. de las Fuerzas Armadas 2, 18014 Granada and 2 Department of Neurosurgery, University Hospital "Reina Sofía", Córdoba, Spain

Correspondence: Dr Maria Angustias Muros, Servicio de Medicina Nuclear, Hospital Virgen de las Nieves, Avda. Fuerzas Armadas, 2, 18014 Granada, Spain

To assess the role of scintigraphy with 111In-DTPA-D-Phe-octreotide (111In-octreotide) in the diagnosis of pituitary adenomas and in the evaluation of post-surgical recurrent or residual tumours, we performed scintigraphy with 111In-DTPA-D-Phe-octreotide (SRS) in 35 patients: 14 patients with confirmed pituitary tumours and 15 with confirmed recurrent tumours. Clinical, biochemical and histological analyses, conventional images (CT/MRI), and follow-up assessments during a period of 1 year to 4 years were recorded in all patients. In the present study, scintigraphy with 111In-octreotide showed positive uptake in 10 out of 14 patients with confirmed pituitary tumour and in 13 out of 15 patients with confirmed recurrent tumour, with an overall sensitivity of 79%. SRS showed better results in growth hormone (GH)- and prolactin (PRL)-secreting tumours (7/8 patients correctly identified) than in other adenomas (3/9). SRS detected recurrence of adenocorticotrophic hormone (ACTH)-secreting tumours (4/5 patients correctly identified) and non-secreting tumours (5/7 patients correctly identified). 111In-octreotide scintigraphy, in combination with other imaging modalities, is useful in the diagnosis and follow-up of pituitary tumours. It allows scar tissue to be differentiated from tumour recurrence after surgical treatment and ensures better selection of patients who will benefit from medical treatment with somatostatin analogues.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2005 by the British Institute of Radiology.